Anna Falk

Anna Falk

Principal Researcher | Docent
Telephone: +46852482897
Visiting address: Solnavägen 9 - kvarter D7, 17165 Solna
Postal address: C4 Neurovetenskap, C4 Forskning Falk, 171 77 Stockholm

About me

  • iPS cell models of human brain development in health and disease.
    I started the Falk lab in 2012 and have since educated four PhD students to
    finalize their PhD degrees with me as their main supervisor. The Falk lab has
    also had numerous amounts of postdocs and bachelor and master students
    through the years.
    I did my PhD at Karolinska Institutet with Professor Jonas Frisén and
    continued with a postdoc in the lab of Professor Austin Smith at the
    University of Cambridge, UK.
    A couple of years ago I did a sabbatical in the lab of Professor Rusty Gage
    at the Salk Institute in San Diego, US.
    I really love my job and I do research since it is rewarding to go from
    ideas, hypothesis, project plan, experimental design, experiments, analysis,
    validating, summarizing, writing a story about novel findings to
    understanding disorders and with the potential to improve human health.
    Selected to the career development programme for young researcher as one of
    ten young research leaders in Sweden across all sciences. This grant (6 MSEK
    from the Swedish Foundation for Strategic Research SSF) provides support for
    successful young scientists to build up their own independent careers.
    Research grant from SciLifeLab/AZ to model human neurological disorders and
    to use the national core facilities at SciLifeLab (20 MSEK)
    I have a Master of Science in Molecular Biology from Umeå University
    PhD in Molecular Biology from Karolinska Institutet about neural stem cells
    Docent (Associate Professor) in Stem cell Biology

Research

  • The Falk lab is deriving cellular models of neural stem cells, neurons and
    glia from iPS cells to study proliferation, differentiation, migration, fate
    choosing mechanisms using assays of transcriptome of bulk or single cells.
    Our studies concentrate mostly on early neurogenesis and modeling of
    neurodevelopment and neuropsychiatric disorders. We have revealed
    neurite outgrowth phenotypes in iPS cell models of Lissencephaly and other
    neurodevelopment disorders. We have on the single cells level investigated
    how iPS cell derived neural stem cells are choosing fate between neurons and
    glia and how that mechanisms is skewed in iPS cells from individuals
    diagnosed with autism and schizophrenia.
    The Falk lab is also driving translational projects investigating the
    regenerative potential of iPS cell derived neural cells in preclinical models
    with the aim to create ATMPs to take iPS derived cell to clinic. We have
    derived one of few clinical compliant GMP iPS cell lines that we have banked
    in a master bank and we are now investigating the route forward to clinic.
    The iPS Core facility at Karolinska Institutet is providing services in the
    area of fibroblast establishment, reprogramming, iPS cell culture, neural
    induction, neural stem cells, neurons, astrocytes, neural crest and soon also
    whole brain organoids. The services are custom-tailored spanning from
    providing vials of frozen cells, to hand-on training, to customers monthly
    subscribing for mature human neurons. The iPS Core is the Swedish "Cell
    vending machine". Get your cell model of interest arrayed in the format you
    need. https://ipscore.se [1]
    *A few recent publications*
    Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR
    Axis that Promotes Malignancy. [2]
    Čančer M, Hutter S, Holmberg KO, Rosén G, Sundström A, Tailor J,
    Bergström T, Garancher A, Essand M, Wechsler-Reya RJ, Falk A, Weishaupt H,
    Swartling FJ
    /Cell Stem Cell 2019 Dec;25(6):855-870.e11/
    Single cell analysis of autism patient with bi-allelic NRXN1-alpha deletion
    reveals skewed fate choice in neural progenitors and impaired neuronal
    functionality. [3]
    Lam M, Moslem M, Bryois J, Pronk RJ, Uhlin E, Ellström ID, Laan L, Olive J,
    Morse R, Rönnholm H, Louhivuori L, Korol SV, Dahl N, Uhlén P, Anderlid BM,
    Kele M, Sullivan PF, Falk A
    /Exp Cell Res 2019 10;383(1):111469/
    Human iPS-Derived Astroglia from a Stable Neural Precursor State Show
    Improved Functionality Compared with Conventional Astrocytic Models. [4]
    Lundin A, Delsing L, Clausen M, Ricchiuto P, Sanchez J, Sabirsh A, Ding M,
    Synnergren J, Zetterberg H, Brolén G, Hicks R, Herland A, Falk A
    /Stem Cell Reports 2018 03;10(3):1030-1045/
    An in vitro model of lissencephaly: expanding the role of DCX during
    neurogenesis. [5]
    Shahsavani M, Pronk RJ, Falk R, Lam M, Moslem M, Linker SB, Salma J, Day K,
    Schuster J, Anderlid BM, Dahl N, Gage FH, Falk A
    /Mol Psychiatry 2018 07;23(7):1674-1684/
    Derivation of human iPS cell lines from monozygotic twins in defined and xeno
    free conditions. [6]
    Uhlin E, Rönnholm H, Day K, Kele M, Tammimies K, Bölte S, Falk A
    /Stem Cell Res 2017 01;18():22-25/
    [1] https://ipscore.se
    [2] https://www.ncbi.nlm.nih.gov/pubmed/31786016
    [3] https://www.ncbi.nlm.nih.gov/pubmed/31302032
    [4] https://www.ncbi.nlm.nih.gov/pubmed/29456185
    [5] https://www.ncbi.nlm.nih.gov/pubmed/28924182
    [6] https://www.ncbi.nlm.nih.gov/pubmed/28395796

Teaching

  • I have been the organizer of a master and PhD courses about cellular
    reprogramming in addition to hand-on course and train for culturing stem
    cells.
    I am continuously lecturing at Karolinska Institutet and other Universities
    and supervising bachelor, master and PhD students.

Articles

All other publications

Grants

  • VINNOVA
    1 October 2021 - 30 September 2026
    Purpose and goal: There are three main aims of IndiCell: 1)Develop iPS cell-based therapy for two model project, Parkinson’s disease and Macular degeneration 2)Create a development pipeline for iPS cell therapies that includes state-of-the-art workflows addressing generic processes, competence and quality controls 3)Become an important global actor within stem cell therapies Expected results and effects: Development of precision medicine with iPS cell therapy for Parkinson’s disease and Macula degeneration. Increase the speed and number of translations of stem cell therapies from pre-clinical transplantations to patients and identify innovation potential in techniques, processes, devices and knowledge. Put Sweden on the global map of stem cell therapies. Increase the awareness of stem cell therapies among the public. Approach and implementation: IndiCell will be executed by implementation of 6 workpackage where 4 will address the process from donation of cells for reprogramming, enter into a specialized GMP facility via production of iPS cells, therapeutic cells, sorting of cells, quality testing of cellular products and then exit of cells from GMP to bedside and local washing and preparation of cells for transplantation to the patient. 2 work packages which deal with monitoring, defining and creating innovations and one dealing with the project management and actively prepare for the future after the Vinnova funding.
  • Swedish Cancer Society
    1 January 2021
    My research group builds cellular models of the human brain using the Nobel Prize-winning reprogramming technique. This technology makes it possible to take a skin cell from a person and then in the lab direct the cell backwards in development to become like an embryonic stem cell. In order to build as similar a model as possible of the human brain, we then use growth factors to direct the stem cells so that they form three-dimensional mini-brains known as organoids. These organoids contain structures and cell types found in the real brain, such as cerebral cortex structure, nerve cells, supporting tissue cells, and neural stem cells. To study how cancer cells build up a brain tumor, it is common for researchers to transplant cancer cells from human tumors into the mouse brain and then follow how the tumor grows and also study how different drugs treat the growth. These are important experiments that in the future may result in new treatments and medicines, the questions I ask in this research project are whether there are alternative methods to these experiments and whether the development of organoids as a model could mimic the animal brain. We plan to create organoids that correspond to the "right" part of the brain to study glioblastoma and medulloblastoma. The goal of this project is to develop and use organoids to replace part of the studies where the researchers transplant tumor cells into animal brains to study tumor growth. We hope to achieve two goals, first to develop these models so that they become useful and thus reduce time, costs and animals. The second goal is to use the organoid models we developed to study medulloblastoma and glioblastoma growth in collaboration with research groups who are experts in cancer research. We expect to answer questions about how important the environment, 3D organization, intrinsic genetic and epigenetic mechanisms are for tumor growth.
  • Swedish Research Council
    1 January 2020 - 31 December 2022
  • Swedish Research Council
    1 December 2017 - 31 December 2019
  • Knut and Alice Wallenberg Foundation
    1 January 2013 - 1 January 2018
  • Swedish Research Council
    1 August 2010 - 31 July 2011

Employments

  • Principal Researcher, Department of Neuroscience, Karolinska Institutet, 2022-

Degrees and Education

  • Docent, Karolinska Institutet, 2014
  • Doctor Of Philosophy, Department of Cell and Molecular Biology, Karolinska Institutet, 2006

News from KI

Events from KI